Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index; 15 of the 21 sources its claims cite were checked for support.

Structural and biophysical comparisons of the pomalidomide- and CC-220-induced interactions of SALL4 with cereblon

Open access

Published version of a preprint

Abstract

The design of cereblon-binding molecular glues (MGs) that selectively recruit a desired protein while excluding teratogenic SALL4 is an area of significant interest when designing therapeutic agents. Previous studies show that SALL4 is degraded in the presence of IKZF1 degraders pomalidomide, and to a lesser extent by CC-220. To expand our understanding of the molecular basis for the interaction of SALL4 with cereblon, we performed biophysical and structural studies demonstrating that SALL4 zinc finger domains one and two (ZF1-2) interact with cereblon (CRBN) in a unique manner. ZF1 interacts with the N-terminal domain of cereblon and ZF2 binds as expected in the C-terminal IMiD-binding domain. Both ZF1 and ZF2 contribute to the potency of the interaction of ZF1-2 with CRBN:MG complexes and the affinities of SALL4 ZF1-2 for the cereblon:CC-220 complex are less potent than for the corresponding pomalidomide complex. Structural analysis provides a rationale for understanding the reduced affinity of SALL4 for cereblon in the presence of CC-220, which engages both ZF1 and ZF2. These studies further our understanding of the molecular glue-mediated interactions of zinc finger-based proteins with cereblon and may provide structural tools for the prospective design of compounds with reduced binding and degradation of SALL4.

Overview

CoChat Summary

TL;DR

This study used SPR and X-ray crystallography to compare how SALL4 zinc fingers bind cereblon in the presence of pomalidomide versus CC-220. It found that SALL4 ZF2 is the main affinity driver, ZF1 adds binding through the CRBN N-terminal domain, and CC-220 produces weaker SALL4 binding than pomalidomide.

Key findings

  • By SPR, SALL4 ZF2(405–432) bound weakly to CRBN:pomalidomide with a KD of 67 μM, but extending ZF2 to include PQVKA improved affinity to 0.98 μM; adding ZF1 further improved affinity 21-fold for ZF2(405–432) and 11-fold for ZF2(405–454).
  • The full ZF1-2 construct was 52-fold more potent than ZF1-2(379–432), which the authors attribute to the C-terminal PQVKA residues; ZF2 was described as the primary determinant of binding affinity.
  • X-ray structures of SALL4 ZF1-2 with DDB1:CRBN:MG complexes were solved at 2.9 Å (CC-220), 3.0 Å (pomalidomide), and 3.1 Å for the longer ZF1-2(370–454) with pomalidomide.
  • For ZF1-2(379–432) K389A, affinity for CRBN:pomalidomide was similar to native (4.4 ± 0.3 μM vs 2.9 ± 0.4 μM), but for CRBN:CC-220 the mutant bound better (64 ± 3.7 μM vs 166 ± 27 μM), supporting a CC-220-specific interaction with K389.

Methods

  • The authors performed surface plasmon resonance (SPR) binding assays using immobilized DDB1:CRBN and a fixed 5 μM concentration of pomalidomide or CC-220 to measure SALL4 zinc-finger interactions.
  • They determined X-ray crystal structures of DDB1:CRBN complexes with SALL4 ZF1-2 and either pomalidomide or CC-220, plus a longer SALL4 construct with pomalidomide.
  • Protein constructs were expressed in E. coli or Sf21 cells and purified by affinity chromatography and size exclusion chromatography; structural comparison and contact analysis were done with MOE.

Limitations

  • The paper does not report a cellular or in vivo test of whether the structural differences translate into differences in SALL4 degradation; this is evident from the text.
  • The structural conclusions are based on truncated SALL4 constructs rather than full-length SALL4; this is evident from the text.
  • The paper does not state all complete SPR datasets in the excerpted text, and some details are deferred to Supplementary Data Table 1; this is stated in the paper.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41598-023-48606-3

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Representative SPR binding data with 1:1 kinetic modelling for the interaction of SALL4 ZF1-2 domains with DDB1:CRBN complexed with pomalidomide (POM) or CC-220. Each plot shows a 2X dilution series of ZF1-2(379–432) or ZF1-2(370–454) at top concentrations and 25 μM and 1 μM, respectively. (a), (b) interaction of SALL4 ZF1-2(379–432) with the CRBN:POM and CRBN:CC-220 complexes, respectively. (c), (d) interaction of SALL4 ZF1-2(370–454) with the CRBN:POM and CRBN:CC220 complexes, respectively.
Figure 1 Representative SPR binding data with 1:1 kinetic modelling for the interaction of SALL4 ZF1-2 domains with DDB1:CRBN complexed with pomalidomide (POM) or CC-220. Each plot shows a 2X dilution series of ZF1-2(379–432) or ZF1-2(370–454) at top concentrations and 25 μM and 1 μM, respectively. (a), (b) interaction of SALL4 ZF1-2(379–432) with the CRBN:POM and CRBN:CC-220 complexes, respectively. (c), (d) interaction of SALL4 ZF1-2(370–454) with the CRBN:POM and CRBN:CC220 complexes, respectively.CC BY · PubMed Central
Figure 2 SALL4 ZF1-2 interacts with CRBN:POM in the DDB1:CRBN:POM:ZF1-2(379–432) complex. (a) Ribbon diagram showing the interaction of SALL4 ZF2 (cyan) and ZF1 (yellow) with the C-terminal IMiD-binding and N-terminal domains of cereblon, respectively, in the presence of pomalidomide (red). (b) The cereblon contact surface area (gray) and SALL4 residues that are proximal with cereblon (c) Space-filling model of SALL4 ZF1-2 in the CRBN:POM:ZF1-2(379–432) complex.
Figure 2 SALL4 ZF1-2 interacts with CRBN:POM in the DDB1:CRBN:POM:ZF1-2(379–432) complex. (a) Ribbon diagram showing the interaction of SALL4 ZF2 (cyan) and ZF1 (yellow) with the C-terminal IMiD-binding and N-terminal domains of cereblon, respectively, in the presence of pomalidomide (red). (b) The cereblon contact surface area (gray) and SALL4 residues that are proximal with cereblon (c) Space-filling model of SALL4 ZF1-2 in the CRBN:POM:ZF1-2(379–432) complex.CC BY · PubMed Central
Figure 3 Comparison of key features in CRBN:MG:ZF1-2 complexes. (a) Representation of the location of ZF1 K389 atoms visible in structures for complexes CRBN:CC-220:ZF1-2(379–432) (magenta/orange/red) and CRBN:POM:ZF1-2(379–432) (green/red/cyan). Cereblon is not visible. (b) The locations of E377 in these complexes. ZF1-2 is omitted for clarity. (c) Comparison of the differences in locations of the NTD (left) and CTD (right) using corresponding residues F150 and E377, respectively. ZF1-2, pomalidomide, and CC-220 are omitted for clarity.
Figure 3 Comparison of key features in CRBN:MG:ZF1-2 complexes. (a) Representation of the location of ZF1 K389 atoms visible in structures for complexes CRBN:CC-220:ZF1-2(379–432) (magenta/orange/red) and CRBN:POM:ZF1-2(379–432) (green/red/cyan). Cereblon is not visible. (b) The locations of E377 in these complexes. ZF1-2 is omitted for clarity. (c) Comparison of the differences in locations of the NTD (left) and CTD (right) using corresponding residues F150 and E377, respectively. ZF1-2, pomalidomide, and CC-220 are omitted for clarity.CC BY · PubMed Central

Verification

Claims the paper makes

9 Valid · 0 Not valid · 4 Not checked · 68 Own results and interpretations

50 more claims

Create a free account to see all 81 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 5
  • It may state two separate claims as one. 24

Create a free account to see these claims.

Citations

Cites

Show all 21 references

Cited by

See all 21

Metadata

Authors
Ma, X., Leon, B., Ornelas, E., Dovala, D., Tandeske, L., Luu, C., Pardee, G., Widger, S., Solomon, J. M., Beckwith, R. E. J., Moser, H., Clifton, M. C., & Wartchow, C. A.
Affiliations
Novartis (United States) (US)
Corresponding author
Wartchow, Charles A.
Venue
Scientific Reports
Published
2023-12-12
Volume
13
Issue
1
Pages
22088-22088
ISSN
2045-2322 (ISSN-L)
OpenAlex
W4389607241
Cited by
21
References
21
Citations by year
2026: 8 · 2025: 6 · 2024: 7
FWCI
1.62
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • Research Square (submittedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • The Novartis Repository (Novartis) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • The Novartis Repository (Novartis) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
Keywords
SALL4, cereblon, pomalidomide, molecular glues, zinc finger, protein-protein interaction, protein structure, binding affinity
MeSH terms
Morpholines, Phthalimides, Piperidones, Teratogens, Thalidomide, Zinc Fingers, Ubiquitin-Protein Ligases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Structural and biophysical comparisons of the pomalidomide- and CC-220-induced interactions of SALL4 with cereblon. https://app.cochat.ai/papers/10.1038/s41598-023-48606-3
The paper
Ma, X., Leon, B., Ornelas, E., Dovala, D., Tandeske, L., Luu, C., Pardee, G., Widger, S., Solomon, J. M., Beckwith, R. E. J., Moser, H., Clifton, M. C., & Wartchow, C. A. (2023). Structural and biophysical comparisons of the pomalidomide- and CC-220-induced interactions of SALL4 with cereblon. Scientific Reports. https://doi.org/10.1038/s41598-023-48606-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.